pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
553
stories
Jul 27, 26
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 27, 26
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
Jul 27, 26
Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
endpoints
Jul 27, 26
Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B
endpoints
Jul 27, 26
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
Jul 27, 26
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
Jul 27, 26
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
Jul 24, 26
Sanofi halts development of troubled immune drug in eczema
biopharma dive
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 24, 26
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
Jul 24, 26
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
Jul 23, 26
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
biospace
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
Jul 22, 26
Summit reports two-year survival data for Western patients, though context lacking
endpoints
Jul 22, 26
Celldex scraps antibody in prurigo nodularis after Phase 2 flop
endpoints
Jul 22, 26
Celldex ends skin disease program after failing phase 2 test
fiercebiotech
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 21, 26
A-Alpha Bio starts AI antibody data consortium with GSK, Boltz
endpoints
Jul 21, 26
Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
fiercebiotech
← prev
page 12 of 19
next →
